ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.
暂无分享,去创建一个
J. Horiot | H. Hamers | M. Piérart | J. Bernier | J. Denekamp | J. Kaanders | O. Dahl | P. Richaud | M. Trovò | A. Rojas | P. Antognoni | M. V. Van Glabbeke
[1] M. Bolla,et al. Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] M. Parmar,et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial , 1997, The Lancet.
[3] J. Kaanders,et al. Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] J. Kaanders,et al. A convenient and reliable method for carbogen breathing in man. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] M. Stratford,et al. Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. , 1993, British Journal of Cancer.
[6] P. Sminia,et al. Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC) , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] J. Overgaard,et al. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] J. Overgaard,et al. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. , 1990, Cancer research.
[9] J. Overgaard,et al. Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. , 1989, International journal of radiation oncology, biology, physics.
[10] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[11] J. Fowler,et al. ARCON--current status: summary of a workshop on preclinical and clinical studies. , 1997, Acta oncologica.
[12] P. Hoskin,et al. Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. , 1996, Acta oncologica.
[13] R. Henriksson,et al. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). , 1994, Acta oncologica.